文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.

作者信息

Pereira Isabela Resende, Vilar-Pereira Glaucia, Marques Virgínia, da Silva Andrea Alice, Caetano Bráulia, Moreira Otacilio Cruz, Machado Alexandre Vieira, Bruna-Romero Oscar, Rodrigues Maurício Martins, Gazzinelli Ricardo Tostes, Lannes-Vieira Joseli

机构信息

Laboratório de Biologia das Interações, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro, Rio de Janeiro, Brazil.

Departamento de Patologia, Universidade Federal Fluminense, Niterói, Rio de Janeiro, Brazil.

出版信息

PLoS Pathog. 2015 Jan 24;11(1):e1004594. doi: 10.1371/journal.ppat.1004594. eCollection 2015 Jan.


DOI:10.1371/journal.ppat.1004594
PMID:25617628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4305326/
Abstract

Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, is a prototypical neglected tropical disease. Specific immunity promotes acute phase survival. Nevertheless, one-third of CD patients develop chronic chagasic cardiomyopathy (CCC) associated with parasite persistence and immunological unbalance. Currently, the therapeutic management of patients only mitigates CCC symptoms. Therefore, a vaccine arises as an alternative to stimulate protective immunity and thereby prevent, delay progression and even reverse CCC. We examined this hypothesis by vaccinating mice with replication-defective human Type 5 recombinant adenoviruses (rAd) carrying sequences of amastigote surface protein-2 (rAdASP2) and trans-sialidase (rAdTS) T. cruzi antigens. For prophylactic vaccination, naïve C57BL/6 mice were immunized with rAdASP2+rAdTS (rAdVax) using a homologous prime/boost protocol before challenge with the Colombian strain. For therapeutic vaccination, rAdVax administration was initiated at 120 days post-infection (dpi), when mice were afflicted by CCC. Mice were analyzed for electrical abnormalities, immune response and cardiac parasitism and tissue damage. Prophylactic immunization with rAdVax induced antibodies and H-2Kb-restricted cytotoxic and interferon (IFN)γ-producing CD8+ T-cells, reduced acute heart parasitism and electrical abnormalities in the chronic phase. Therapeutic vaccination increased survival and reduced electrical abnormalities after the prime (analysis at 160 dpi) and the boost (analysis at 180 and 230 dpi). Post-therapy mice exhibited less heart injury and electrical abnormalities compared with pre-therapy mice. rAdVax therapeutic vaccination preserved specific IFNγ-mediated immunity but reduced the response to polyclonal stimuli (anti-CD3 plus anti-CD28), CD107a+ CD8+ T-cell frequency and plasma nitric oxide (NO) levels. Moreover, therapeutic rAdVax reshaped immunity in the heart tissue as reduced the number of perforin+ cells, preserved the number of IFNγ+ cells, increased the expression of IFNγ mRNA but reduced inducible NO synthase mRNA. Vaccine-based immunostimulation with rAd might offer a rational alternative for re-programming the immune response to preserve and, moreover, recover tissue injury in Chagas' heart disease.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/253e113adc98/ppat.1004594.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/045e89241867/ppat.1004594.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/53cece6c171e/ppat.1004594.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/bf77566a815e/ppat.1004594.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/30babdf4382d/ppat.1004594.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/1609ff6d48d9/ppat.1004594.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/6675c099256a/ppat.1004594.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/253e113adc98/ppat.1004594.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/045e89241867/ppat.1004594.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/53cece6c171e/ppat.1004594.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/bf77566a815e/ppat.1004594.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/30babdf4382d/ppat.1004594.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/1609ff6d48d9/ppat.1004594.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/6675c099256a/ppat.1004594.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc42/4305326/253e113adc98/ppat.1004594.g007.jpg

相似文献

[1]
A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.

PLoS Pathog. 2015-1-24

[2]
A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Hum Vaccin Immunother. 2016-4-2

[3]
Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase.

Hum Gene Ther. 2006-9

[4]
Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

Infect Immun. 2009-10

[5]
Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi.

Infect Immun. 2011-2-28

[6]
TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

PLoS One. 2013-3-26

[7]
Therapeutic Efficacy of a Subunit Vaccine in Controlling Chronic Trypanosoma cruzi Infection and Chagas Disease Is Enhanced by Glutathione Peroxidase Over-Expression.

PLoS One. 2015-6-15

[8]
CCL3/Macrophage Inflammatory Protein-1α Is Dually Involved in Parasite Persistence and Induction of a TNF- and IFNγ-Enriched Inflammatory Milieu in -Induced Chronic Cardiomyopathy.

Front Immunol. 2020

[9]
Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells.

Vaccine. 2010-9-16

[10]
Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase.

Hum Gene Ther. 2004-9

引用本文的文献

[1]
Heterologous prime-boost immunization based on a human adenovirus 5 vectored containing Trichinella spiralis Cystatin-like protein elicits protective mucosal immunity in mice.

PLoS Negl Trop Dis. 2025-7-16

[2]
Randomized field trial of a therapeutic vaccine against natural infection in dogs and correlates for efficacy.

bioRxiv. 2025-5-14

[3]
The time has come for a vaccine against Chagas disease.

Lancet Reg Health Am. 2025-3-21

[4]
Research advances in replication-deficient viral vector vaccines.

Front Vet Sci. 2025-3-3

[5]
An Update on Vaccines Against and Chagas Disease.

Pathogens. 2025-1-30

[6]
Immunomodulatory activity of Trypanosoma cruzi recombinant antigen combination TSA-1-C4 and Tc24-C4 induce activation of macrophages and CD8 T cells.

Parasitol Res. 2025-1-24

[7]
Influence of angiotensin II type 1 receptors and angiotensin-converting enzyme I/D gene polymorphisms on the progression of Chagas' heart disease in a Brazilian cohort: Impact of therapy on clinical outcomes.

PLoS Negl Trop Dis. 2024-11-26

[8]
The beneficial effect of fluoxetine on behavioral and cognitive changes in chronic experimental Chagas disease unveils the role of serotonin fueling astrocyte infection by Trypanosoma cruzi.

PLoS Negl Trop Dis. 2024-5

[9]
Harnessing RNA Technology to Advance Therapeutic Vaccine Antigens against Chagas Disease.

ACS Appl Mater Interfaces. 2024-4-3

[10]
mRNA and Adenoviral Vector Vaccine Platforms Utilized in COVID-19 Vaccines: Technologies, Ecosystem, and Future Directions.

Vaccines (Basel). 2023-11-21

本文引用的文献

[1]
Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas' heart disease.

Mediators Inflamm. 2014

[2]
Severity of chronic experimental Chagas' heart disease parallels tumour necrosis factor and nitric oxide levels in the serum: models of mild and severe disease.

Mem Inst Oswaldo Cruz. 2014-6

[3]
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

N Engl J Med. 2013-10-7

[4]
A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity.

Sci Transl Med. 2013-10-2

[5]
Vaccination using recombinants influenza and adenoviruses encoding amastigote surface protein-2 are highly effective on protection against Trypanosoma cruzi infection.

PLoS One. 2013-4-24

[6]
TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice.

PLoS One. 2013-3-26

[7]
Modeling the economic value of a Chagas' disease therapeutic vaccine.

Hum Vaccin Immunother. 2012-8-16

[8]
Trypanosoma cruzi-induced depressive-like behavior is independent of meningoencephalitis but responsive to parasiticide and TNF-targeted therapeutic interventions.

Brain Behav Immun. 2012-7-25

[9]
Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine.

PLoS Pathog. 2012-5-17

[10]
Inducible nitric oxide synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: association with heart injury.

PLoS Negl Trop Dis. 2012-5-8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索